NEW YORK (GenomeWeb News) – Galapagos said today that it has expanded a preclinical development agreement to discover, screen, and validate drug targets that Merck will develop and take to market.

The agreement, which could be worth as much as €400 million ($596 million), adds atherosclerosis drug targets to an earlier one that covered targets for obesity and diabetes.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.